Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Intracerebral Hemorrhage
Journal publishes results of acute intracerebral hemorrhage study
March 24th, 2005
Novo Nordisk Inc. announced the results of a recently completed clinical trial of NovoSeven Coagulation Factor VIIa (Recombinant) in patients with acute intracerebral hemorrhage (ICH) as published in the New England Journal of Medicine (NEJM). The NEJM article, "Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage," presents the results of the largest clinical trial ever conducted with a pharmacologic agent for the treatment of ICH. The study found a reduction in hematoma growth (bleeding in the brain), decreased mortality, and improvement in neurological and clinical outcomes in patients treated with NovoSeven compared to placebo. ...
Source: Women's Health Weekly (2005-03-24)
|
